2Renshaw AA, Young NA, Birdsong GG, et al. Comparison of performance of conventional and Thinprep gynecologicp reparations in the College of American Pathologists Gynecologic Cytology Program [J]. Arch Pathol Lab Med, 2004, 128(1): 17-22.
3Nance KV. Evolution of Pap testifig at a community hospital: a ten year experience [J]. Diagn Cytopathol, 2007, 35(3): 148-153.
4Solomon D, DaveyD, Kurman R, et al. The 2001 Bethesda System: Terminology for reporting results of cervical cytology[J]. JAMA, 2002, 287 (16) : 2114-2119.
5Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication [ J]. lnt J Cancer,2011,128 (4) :927 - 935.
6Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccina- tion: mathematical modelling analyses [ J ]. Plos Med, 2006, 3 (5) :e138.
7Kjaer S, Hcgdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period[J]. Cancer Res,2006,66(21 ) : 10630 - 10636.
8Clifford GM, Franeeehi S, Diaz M, et al. Chapter 3 : HPV type distri- bution in women with and without cervical neoplastic diseases [ J ]. Vaccine ,2006,24 : s3/26 - s3/34.
9Lifford GM, Rana RK, Francesehi S, et al. Human papillomavirus gen- otype distribution in low-grade cervical lesions: compariosn by geo- graphic region and with cervical cancer [ J ]. Cancer Epidemiol Bio- markers Prey,2005,14(5) :1157 - 1164.
10The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnosis: developed and approved at the National Institute Workshop in Bethesda, MD, December 12-13, 1988. Diagn Cytopathol, 1989, 5:331-334.
